Yiu ZZN, Mason KJ, Hampton PJ, et al. - Between November 2007 and August 2019, a prospective cohort study was conducted in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) to evaluate the relative drug survival of adalimumab, ustekinumab, and secukinumab in patients with psoriasis, and to examine for predictors for biologic drug survival. Five thousand five hundred forty-two starting on adalimumab; 991, secukinumab; and 3118 on ustekinumab have been involved. According to findings, secukinumab and ustekinumab have comparable sustained drug survival, whereas in individuals with psoriasis, adalimumab has a lower drug survival. Predictors of differential effects between the biologic therapies were psoriatic arthritis and prior biologic experience.